Sanguina
A wellness tool company that focuses on the development and distribution of simple and standalone point-of-care diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
* | $2.8m | Series A | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | - | 29 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Sanguina operates in the healthcare technology market, focusing on at-home health diagnostics. The company’s flagship product, AnemoCheck, is an FDA-cleared home anemia test that measures hemoglobin levels through the color of fingernail capillary beds. This innovative approach allows users to screen for anemia without the need for traditional blood tests. Sanguina primarily serves individuals concerned about their health and looking for convenient, at-home solutions. The company generates revenue through the sale of its AnemoCheck app, available on Google Play and iOS App Stores, and potentially through partnerships with healthcare providers and insurers. Sanguina’s business model is centered around providing accessible, user-friendly health diagnostics that empower individuals to monitor their health from the comfort of their homes. The company has received recognition in peer-reviewed journals and has secured patents in the U.S., Europe, and Japan, underscoring its commitment to innovation and reliability.
Keywords: anemia, hemoglobin, diagnostics, healthcare, technology, FDA-cleared, app, fingernail analysis, at-home testing, innovation.